Clinical trials: Neoplasms，Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
SPGL008 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell Lung Cancer
This study is an open, multicenter, phase 2 clinical trial of SPGL008 in combination with SSGJ-706 ± chemotherapy for the treatment of advanced non-small cell lung cancer.
- Trial name
- NCT07874984
- Testing
- SSGJ-706, SPGL008, Chemotherapy
- Volunteers
- 220 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Lung Adenocarcinoma, Stage IV Non-small Cell Lung Cancer
Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma
In order to further evaluate the efficacy of immunotherapy combined with antivascular therapy in the real world, we used Serpluimab combined with Bevacizumab and platinum-based chemotherapy in previously untreated…
- Conditions
- Lung Adenocarcinoma, Stage IV Non-small Cell Lung Cancer, PD-1 Inhibitor, VEGF
- Trial name
- NCT05675033
- Testing
- Serplulimab and Bevacizumab injection
- Volunteers
- 50 people
- Sponsor
- Fujian Cancer Hospital
Stage IIIA Non-Small Cell Lung Cancer
Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery
This phase II trial studies how well fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET)/computed tomography (CT) works in predicting response to chemotherapy in patients with stage IIIA non-small cell lung cancer…
- Trial name
- NCT02607423
- Testing
- Cisplatin, Computed Tomography, Docetaxel
- Where
- United States
- Sponsor
- ECOG-ACRIN Cancer Research Group
HIV Infection, Recurrent Non-Small Cell Lung Carcinoma
Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection
This phase I trial studies the side effects and best dose of erlotinib hydrochloride in treating non-small cell lung cancer that has spread to other parts of the body or cannot be removed by surgery in patients with human…
- Conditions
- HIV Infection, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
- Trial name
- NCT02134886
- Testing
- Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Radiation Induced Lung Injury, Non Small Cell Lung Cancer
Hyperpolarized Noble Gas MRI Detection of Radiation-Induced Lung Injury
Lung cancer is the leading cause of cancer death in the world; each year lung cancer claims over 20 000 lives in Canada and more than one million lives globally (1).
- Trial name
- NCT03632369
- Testing
- Hyperpolarized xenon-129 MRI
- Volunteers
- healthy volunteers welcome
- Sponsor
- Thunder Bay Regional Health Research Institute
Non Small Cell Lung Cancer
Assessment of Video Assisted Thoracoscopic Surgery (VATS) Versus Open Surgery for Patients Undergoing Lobectomy
Assessment of VATS versus standard open surgery for treatment of non small cell lung cancer.
- Trial name
- NCT00912366
- Testing
- Lobectomy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Medtronic - MITG
Metastatic Non-Small Cell Lung Carcinoma
Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX
This is a single center, open-label, single arm study in patients with metastatic non-small cell lung cancer (NSCLC) expressing PD-L1 after failure of platinum-based combination chemotherapy.
- Trial name
- NCT03134456
- Testing
- Pembrolizumab Injection
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Samsung Medical Center
Carcinoma, Non-Small-Cell Lung
Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC)
PI-88 is a new experimental drug that inhibits tumour growth by reducing the formation of new blood vessels into tumours. Docetaxel is a standard second-line treatment offered to patients with non-small-cell lung cancer who…
- Trial name
- NCT00097851
- Testing
- docetaxel, PI-88
- Where
- 13 sites in Australia
- Volunteers
- 100 people
- Sponsor
- Cellxpert Biotechnology Corp.
Non-Small Cell Lung Cancer
Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer
The main objective of this study is to determine recommended phase II dose and safety of tetrathiomolybdate (TM) in combination with carboplatin and pemetrexed in chemo-naive metastatic or recurrent non-squamous non-small cell…
- Trial name
- NCT01837329
- Testing
- Tetrathiomolybdate
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Rochester
Non-small Cell Lung Cancer Stage IB (Resectable), Non-small Cell Lung Cancer Stage II (Resectable)
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer
Lung cancer is the chief cause of cancer death. The new standard-of-care (SOC) in operable lung cancer combines chemotherapy and an immune-stimulating drug before the surgery (neoadjuvant approach).
- Conditions
- Non-small Cell Lung Cancer Stage IB (Resectable), Non-small Cell Lung Cancer Stage II (Resectable), Non-small Cell Lung Cancer Stage ⅢA (Resectable)
- Trial name
- Pre-PLaN (NCT06250829)
- Testing
- Observational
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
The purpose of this study is to evaluate the safety and efficacy of zipalertinib in combination with standard first-line platinum-based chemotherapy compared to chemotherapy alone, in patients with locally advanced or metastatic…
- Trial name
- REZILIENT3 (NCT05973773)
- Testing
- TAS6417
- Where
- 110 sites in United States, Belgium and 20 more
- Volunteers
- 285 people
- Sponsor
- Taiho Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
Blood-based Identification and Monitoring of Patients With ALK-translocated Lung Cancer
Genetic rearrangements in the Anaplastic Lymphoma Kinase (ALK) gene result in the creation of a variety of oncogenic fusion proteins that drive malignancy in a subset of non-small cell lung cancers (NSCLC) patients.
- Trial name
- NCT02718651
- Where
- Denmark
- Volunteers
- 70 people
- Sponsor
- University of Aarhus
MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
The main aims of this study are to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or the recommended combination dose of Anvumetostat in combination with IDE397 in adult participants with…
- Trial name
- NCT05975073
- Testing
- Anvumetostat, IDE397
- Where
- 27 sites in United States, Australia and 5 more
- Volunteers
- 53 people
- Sponsor
- Amgen
Non-small Cell Lung Cancer, Non-small Cell Carcinoma
Combining ICI With SBRT or HypoFrx-RT for ES NSCLC
This study will explore the best dose of radiation to be used when treating stage I-III non-small cell lung cancer (NSCLC) with stereotactic body radiation therapy (SBRT) or hypo-fractionated radiotherapy (HypoFrx-RT) that is…
- Conditions
- Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II
- Trial name
- NCT05451173
- Testing
- Stereotactic body radiotherapy, Hypofractionated radiotherapy, Durvalumab
- Where
- China
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Alexander Chi
Gastric Cancer, Renal Cell Carcinoma
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study.
- Conditions
- Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma
- Trial name
- NCT05238883
- Testing
- HFB200301, Tislelizumab
- Where
- 10 sites in United States, Spain
- Volunteers
- 72 people
- Sponsor
- HiFiBiO Therapeutics
Non Small Cell Lung Cancer, BRCA1 Mutation
Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma
Primary objective: · Progression free survival. Secondary objectives: Assess Overall survival of both treatment groups. Assess Tumor response rate using RECIST criteria Assess Toxicity profile of patients enrolled in the study.
- Trial name
- BREC (NCT00617656)
- Testing
- Cisplatin, Docetaxel, Gemcitabine, Cisplatin, Docetaxel, Cisplatin
- Where
- 44 sites in Spain
- Volunteers
- 382 people
- Sponsor
- Spanish Lung Cancer Group
Non-Small Cell Lung Cancer, Renal Cell Carcinoma
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor…
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Colorectal Carcinoma
- Trial name
- NCT05783622
- Testing
- JANX008
- Where
- 18 sites in United States
- Volunteers
- 130 people
- Sponsor
- Janux Therapeutics
Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC)
QLS5132 Combination Therapy in Advanced Solid Tumors
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics (PK), and effectiveness of the investigational drug QLS5132 (injectable) in combination with other therapies for participants with advanced…
- Conditions
- Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer, Advanced Solid Tumors
- Trial name
- NCT07453394
- Testing
- QLS5132; Bevacizumab, QLS5132; Platinum; Bevacizumab, QLS5132; Olaparib; Bevacizumab
- Volunteers
- 626 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Lung Cancer, Non-Small Cell
Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer
The primary purpose of this study is to evaluate the safety and tolerability of the combination therapy of trametinib and docetaxel with growth factor support in Japanese subjects with Stage IV or a postoperative recurrence…
- Trial name
- NCT01938456
- Testing
- Trametinib, Docetaxel, Filgrastim
- Sponsor
- GlaxoSmithKline
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
This clinical trial studies image-guided hypofractionated radiation therapy (RT) when given together with hypofractionated RT boost and combination chemotherapy in treating patients with stage II-III non-small cell lung cancer…
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT01345851
- Testing
- hypofractionated radiation therapy, laboratory biomarker analysis, image-guided radiation therapy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Jonsson Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.